Bausch Health Companies Inc. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amortization, Amount
Bausch Health Companies Inc. (BHC) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amortization, Amount of $0 for the 12-month period ending 2014-12-31, per its 10-K filed 2015-02-25.
Discontinued › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationNondeductibleExpenseAmortization · last filed 2015-02-25
- Bausch Health Companies Inc. effective income tax rate reconciliation, nondeductible expense, amortization, amount for fiscal 2014 was $0.00.
- Bausch Health Companies Inc. effective income tax rate reconciliation, nondeductible expense, amortization, amount for fiscal 2013 was $0.00, a 100.00% decline from fiscal 2012.
- Bausch Health Companies Inc. effective income tax rate reconciliation, nondeductible expense, amortization, amount for fiscal 2012 was $6.20M, a 72.14% decline from fiscal 2011.
- Bausch Health Companies Inc. effective income tax rate reconciliation, nondeductible expense, amortization, amount for fiscal 2011 was $22.25M, a 21.56% increase from fiscal 2010.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amortization, Amount 12 month | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amortization, Amount 12 month as first filed |
|---|---|---|
| 2014-12-31 | $0.00 10-K · filed 2015-02-25 | |
| 2013-12-31 | $0.00 10-K · filed 2015-02-25 | |
| 2012-12-31 | $6.20M 10-K · filed 2015-02-25 | $6.17M 10-K · filed 2013-02-28 |
| 2011-12-31 | $22.25M 10-K · filed 2014-02-28 | |
| 2010-12-31 | $18.30M 10-K · filed 2013-02-28 | |
| 2009-12-31 | $11.96M 10-K · filed 2012-02-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 |